Acrivon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-80.56	-60.39	-31.17	-16.24	-5.31
Depreciation & Amortization	1.01	0.54	0.36	0.04	0.01
Loss (Gain) From Sale of Investments	-3.78	-3.32	-0.7	-	-
Stock-Based Compensation	14.29	11.62	2.19	0.5	0
Other Operating Activities	0.93	0.78	0.73	1.4	2.17
Change in Accounts Payable	-3.59	3.61	-0.25	0.8	0.08
Change in Other Net Operating Assets	6.02	4.53	-1.29	-0.47	0.24
Operating Cash Flow	-65.67	-42.64	-30.12	-13.98	-2.8
Capital Expenditures	-2.77	-1.29	-2.17	-0.24	-0.02
Investment in Securities	-49	52.01	-139.51	-	-
Investing Cash Flow	-51.77	50.72	-141.68	-0.24	-0.02
Long-Term Debt Issued	-	-	-	-	0.06
Net Debt Issued (Repaid)	-	-	-	-	0.06
Issuance of Common Stock	70.09	0.78	104.48	0	-
Repurchase of Common Stock	-2.52	-1.3	-	-	-
Other Financing Activities	53.46	-1.03	-2.77	-	-
Financing Cash Flow	121.03	-1.55	101.71	112.22	2.89
Net Cash Flow	3.59	6.52	-70.08	98	0.07
Free Cash Flow	-68.44	-43.93	-32.28	-14.22	-2.82
Free Cash Flow Per Share	-2.02	-1.99	-7.83	-8.16	-1.97
Levered Free Cash Flow	-39.41	-22.33	-20.03	-8.79	-
Unlevered Free Cash Flow	-39.41	-22.33	-20.03	-8.79	-
Change in Net Working Capital	-3.82	-8.75	-0	-1.03	-

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q